{
    "nct_id": "NCT03502616",
    "official_title": "A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)",
    "inclusion_criteria": "* Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).\n* Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.\n* Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of known or suspected complete ankylosis of the spine.\n* History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.\n* History of any other rheumatic disease.\n* Any subject with condition affecting oral drug absorption.",
    "miscellaneous_criteria": ""
}